#BEGIN_DRUGCARD DB00916

# AHFS_Codes:
08:30.92
84:04.04
84:04.92

# ATC_Codes:
A01AB17
D06BX01
G01AF01
J01XD01
P01AB01

# Absorption:
Well absorbed (at least 80%) with peak plasma concentrations achieved in 1-3 hours following oral administration of therapeutic doses of immediate release formulation.

# Biotransformation:
Hepatic metabolism by hydroxylation, oxidation, and glucuronidation.

# Brand_Mixtures:
Helidac (Metronidazole + Bismuth subsalicylate + tetracycline hydrochloride)

# Brand_Names:
Acromona
Anagiardil
Apo-Metronidazole
Arilin
Atrivyl
Bayer 5360
Bexon
Clont
Cont
Danizol
Deflamon
Deflamon-Wirkstoff
Efloran
Elyzol
Entizol
Eumin
Flagemona
Flagesol
Flagil
Flagyl
Flagyl ER
Flagyl I.V.
Flegyl
Fossyol
Giatricol
Gineflavir
Klion
Klont
Meronidal
Metric 21
Metro Cream
Metro I.V.
Metro I.V. In Plastic Container
Metrocream
Metrogel
Metrogel-Vaginal
Metrolag
Metrolotion
Metrolyl
Metromidol
Metronidaz
Metrotop
Mexibol
Monagyl
Monasin
Nalox
Neo-Tric
Nida
Nidagel
Noritate
Novonidazol
Orvagil
Protostat
Rathimed
Sanatrichom
Satric
Takimetol
Trichazol
Trichex
Tricho Cordes
Tricho-Gynaedron
Trichocide
Trichomol
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
Vagilen
Vagimid
Vertisal
Wagitran
Zadstat

# CAS_Registry_Number:
443-48-1

# ChEBI_ID:
6909

# Chemical_Formula:
C6H9N3O3

# Chemical_IUPAC_Name:
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
649074

# Description:
A nitroimidazole used to treat amebiasis; vaginitis; trichomonas infections; giardiasis; anaerobic bacteria; and treponemal infections. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed).

# Dosage_Forms:
Capsule	Oral
Cream	Intravaginal
Cream	Topical
Gel	Intravaginal
Gel	Topical
Liquid	Intravenous
Lotion	Topical
Solution	Intravenous
Tablet	Oral
Tablet, extended release	Oral

# Drug_Category:
Anti-Infective Agents
Anti-Infectives
Antiprotozoal Agents
Antiprotozoals
Radiation-Sensitizing Agents

# Drug_Interactions:
Acenocoumarol	Metronidazole may increase the anticoagulant effect of acenocoumarol.
Amobarbital	The barbiturate, amobarbital, decreases the effect of metronidazole.
Amprenavir	Increased risk of side effects (oral solution)
Anisindione	Metronidazole may increase the anticoagulant effect of anisindione.
Aprobarbital	The barbiturate, aprobarbital, decreases the effect of metronidazole.
Busulfan	Metronidazole increases the effect/toxicity of busulfan
Butabarbital	The barbiturate, butabarbital, decreases the effect of metronidazole.
Butalbital	The barbiturate, butalbital, decreases the effect of metronidazole.
Butethal	The barbiturate, butethal, decreases the effect of metronidazole.
Carbamazepine	Metronidazole increases the effect of carbamazepine
Dicumarol	Metronidazole may increase the anticoagulant effect of dicumarol.
Dihydroquinidine barbiturate	The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole.
Disulfiram	Possible acute psychosis and confusion
Fluorouracil	Risk of 5-FU toxicity when associated with metronidazole
Heptabarbital	The barbiturate, heptabarbital, decreases the effect of metronidazole.
Hexobarbital	The barbiturate, hexobarbital, decreases the effect of metronidazole.
Lithium	Metronidazole increases the effect and toxicity of lithium
Methohexital	The barbiturate, methohexital, decreases the effect of metronidazole.
Methylphenobarbital	The barbiturate, methylphenobarbital, decreases the effect of metronidazole.
Pentobarbital	The barbiturate, pentobarbital, decreases the effect of metronidazole.
Phenobarbital	The barbiturate, phenobarbital, decreases the effect of metronidazole.
Primidone	The barbiturate, primidone, decreases the effect of metronidazole.
Quinidine barbiturate	The barbiturate, quinidine barbiturate, decreases the effect of metronidazole.
Secobarbital	The barbiturate, secobarbital, decreases the effect of metronidazole.
Tacrolimus	Metronidazole increases the levels/toxicity of tacrolimus
Talbutal	The barbiturate, talbutal, decreases the effect of metronidazole.
Tamsulosin	Metronidazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Metronidazole is initiated, discontinued, or dose changed.
Tolterodine	Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Tramadol	Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Trazodone	The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed.
Warfarin	Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed.

# Drug_Reference:
10676835	Williams CS, Woodcock KR: Do ethanol and metronidazole interact to produce a disulfiram-like reaction? Ann Pharmacother. 2000 Feb;34(2):255-7.
12022894	Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP: Lack of disulfiram-like reaction with metronidazole and ethanol. Ann Pharmacother. 2002 Jun;36(6):971-4.
15715599	Lamont RF: Can antibiotics prevent preterm birth--the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73.
16398774	Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. 2006 Jan;113(1):65-74.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.02

# Experimental_Logs:
-1.26

# Experimental_Water_Solubility:
9500 mg/L (at 25 °C)

# Food_Interactions:
Avoid alcohol.
Take with food to reduce irritation.

# GenBank_ID:
Not Available

# Generic_Name:
Metronidazole

# HET_ID:
Not Available

# Half_Life:
6-8 hours

# InChI_Identifier:
InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

# InChI_Key:
InChIKey=VAOCPAMSLUNLGC-UHFFFAOYSA-N

# Indication:
For the treatment of anaerobic infections and mixed infections, surgical prophylaxis requiring anaerobic coverage, Clostridium difficile-associated diarrhea and colitis, Helicobacter pylori infection and duodenal ulcer disease, bacterial vaginosis, Giardia lamblia gastro-enteritis, amebiasis caused by Entamoeba histolytica, acne rosacea (topical treatment), and Trichomonas infections.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00409

# LIMS_Drug_ID:
916

# Mechanism_Of_Action:
Metronidazole is a prodrug. Unionized metronidazole is selective for anaerobic bacteria due to their ability to intracellularly reduce metronidazole to its active form. This reduced metronidazole then covalently binds to DNA, disrupt its helical structure, inhibiting bacterial nucleic acid synthesis and resulting in bacterial cell death.

# Melting_Point:
160.5 °C

# Molecular_Weight_Avg:
171.154

# Molecular_Weight_Mono:
171.064391169

# Organisms_Affected:
Bacteria and protozoa

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450484

# Pharmacology:
Metronidazole, a synthetic antibacterial and antiprotozoal agent of the nitroimidazole class, is used against protozoa such as <i>Trichomonas vaginalis</i>, amebiasis, and giardiasis. Metronidazole is extremely effective against anaerobic bacterial infections and is also used to treat Crohn's disease, antibiotic-associated diarrhea, and rosacea.

# Predicted_LogP_Hydrophobicity:
-0.15

# Predicted_LogS:
-1.5

# Predicted_Water_Solubility:
5.92e+00 g/l

# Primary_Accession_No:
DB00916

# Protein_Binding:
Less than 20% bound to plasma proteins.

# PubChem_Compound_ID:
4173

# PubChem_Substance_ID:
46508911

# RxList_Link:
http://www.rxlist.com/cgi/generic/metron.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00631

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=NC=C(N1CCO)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Methronidazole
Metronidazol
Metronidazole Benzoate
Metronidazole Hcl
Metronidazole in Plastic Container
Metronidazolo

# Synthesis_Reference:
Not Available

# Toxicity:
LD50=500 mg/kg/day (orally in rat). Adverse effects include reversible peripheral neuropathy with prolonged therapy, CNS toxicity, disulfiram effect with alcohol, dark red-brown urine, metallic taste, nausea, epigastric distress, dizziness, vertigo and paresthesias associated with high doses, and neutropenia (reversible and mild).

# Update_Date:
2013-02-08 16:19:45 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Metronidazole

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_2_ID:
4757

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_3_ID:
4924

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P10632

# Drug_Target_1_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17914922	Salles JM, Salles MJ, Moraes LA, Silva MC: Invasive amebiasis: an update on diagnosis and management. Expert Rev Anti Infect Ther. 2007 Oct;5(5):893-901.
17924465	Li AQ, Dai N, Yan J, Zhu YL: [Screening for metronidazole-resistance associated gene fragments of Helicobacter pylori by suppression subtractive hybridization.] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 Sep;36(5):465-9.
8444678	Edwards DI: Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993 Jan;31(1):9-20.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_1_General_Function:
Biological information storage and information transfer

# Drug_Target_1_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
874

# Drug_Target_1_Locus:
All loci

# Drug_Target_1_Molecular_Weight:
7656 (double strand)

# Drug_Target_1_Name:
DNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1BNA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Deoxyribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10543743	Debets-Ossenkopp YJ, Pot RG, van Westerloo DJ, Goodwin A, Vandenbroucke-Grauls CM, Berg DE, Hoffman PS, Kusters JG: Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637. Antimicrob Agents Chemother. 1999 Nov;43(11):2657-62.
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
10960092	Sisson G, Jeong JY, Goodwin A, Bryden L, Rossler N, Lim-Morrison S, Raudonikiene A, Berg DE, Hoffman PS: Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. J Bacteriol. 2000 Sep;182(18):5091-6.
12654749	Chisholm SA, Owen RJ: Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother. 2003 Apr;51(4):995-9. Epub 2003 Mar 13.
19378102	Pisharath H, Parsons MJ: Nitroreductase-mediated cell ablation in transgenic zebrafish embryos. Methods Mol Biol. 2009;546:133-43.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
rdxA

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6945

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Oxygen-insensitive NADPH nitroreductase

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
O25608

# Drug_Target_2_SwissProt_Name:
RDXA_HELPY

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Periplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
16550436	Kutty R, Bennett GN: Studies on inhibition of transformation of 2,4,6-trinitrotoluene catalyzed by Fe-only hydrogenase from Clostridium acetobutylicum. J Ind Microbiol Biotechnol. 2006 May;33(5):368-76. Epub 2006 Jan 28.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M81737

# Drug_Target_3_GenBank_ID_Protein:
144836

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
>1725 bp
ATGAAAACAATAATTATAAATGGTGTACAGTTTAATACTGATGAAGACACTACTATATTA
AAATTTGCACGAGACAACAATATTGATATATCTGCACTGTGTTTTTTAAATAATTGTAAT
AATGACATAAATAAGTGTGAAATATGTACTGTAGAGGTAGAGGGTACTGGATTAGTAACA
GCCTGTGATACATTAATTGAGGATGGTATGATTATAAACACAAATTCCGATGCTGTCAAC
GAAAAAATTAAATCTAGAATATCTCAATTATTAGACATACATGAATTCAAATGTGGTCCT
TGCAATAGAAGAGAAAACTGTGAATTCTTAAAACTTGTTATAAAATATAAAGCAAGAGCT
TCTAAACCATTTTTACCTAAAGATAAGACTGAATATGTAGATGAAAGAAGTAAATCATTA
ACTGTAGATAGGACAAAATGCTTATTATGTGGAAGATGTGTTAATGCCTGTGGAAAAAAT
ACTGAAACCTATGCAATGAAATTTTTAAACAAAAATGGTAAAACTATAATTGGAGCAGAG
GATGAAAAATGCTTTGATGATACTAATTGTCTATTATGTGGTCAATGTATAATCGCCTGT
CCAGTAGCAGCATTATCGGAAAAATCACACATGGATAGAGTAAAAAATGCCTTAAATGCC
CCTGAAAAACATGTAATAGTAGCTATGGCTCCATCTGTCAGAGCTTCTATAGGTGAACTT
TTTAATATGGGATTTGGCGTTGACGTAACAGGAAAAATTTATACTGCTTTAAGACAGCTT
GGATTTGATAAAATATTCGATATAAACTTCGGAGCAGATATGACAATTATGGAAGAGGCT
ACAGAATTAGTTCAAAGAATAGAGAATAATGGACCTTTCCCAATGTTTACATCTTGCTGC
CCAGGTTGGGTAAGACAAGCTGAAAATTATTATCCTGAATTACTAAATAATCTTTCATCA
GCTAAATCACCTCAACAAATTTTTGGTACTGCTAGTAAAACTTATTATCCTTCTATATCT
GGTCTTGACCCAAAGAATGTATTTACTGTAACAGTTATGCCCTGTACTTCAAAAAAATTT
GAAGCAGATAGACCACAAATGGAAAAAGACGGCCTAAGAGATATAGATGCTGTTATAACT
ACTCGAGAATTAGCAAAAATGATTAAAGATGCTAAAATACCATTTGCTAAACTTGAAGAT
AGCGAAGCAGACCCTGCTATGGGAGAATACAGCGGTGCTGGTGCCATATTTGGTGCAACT
GGCGGAGTTATGGAAGCAGCTTTAAGAAGTGCAAAAGACTTTGCTGAAAACGCTGAACTT
GAAGATATAGAATATAAGCAAGTTAGAGGATTAAATGGTATAAAAGAAGCTGAAGTAGAA
ATAAATAACAACAAATATAATGTAGCTGTTATAAATGGTGCTTCAAATTTATTTAAGTTT
ATGAAATCTGGTATGATTAACGAAAAACAATATCATTTCATAGAAGTAATGGCTTGTCAT
GGAGGATGTGTAAATGGTGGTGGACAGCCTCATGTAAACCCAAAAGATTTAGAAAAAGTA
GACATAAAAAAAGTAAGAGCTTCTGTATTGTATAATCAGGATGAACATCTTTCCAAGAGA
AAATCTCATGAAAATACTGCATTAGTTAAAATGTATCAAAATTATTTTGGCAAACCAGGT
GAAGGTCGTGCCCATGAAATATTACACTTTAAATATAAAAAATAA

# Drug_Target_3_General_Function:
Involved in electron carrier activity

# Drug_Target_3_General_References:
10529166	Lemon BJ, Peters JW: Binding of exogenously added carbon monoxide at the active site of the iron-only hydrogenase (CpI) from Clostridium pasteurianum. Biochemistry. 1999 Oct 5;38(40):12969-73.
1911757	Meyer J, Gagnon J: Primary structure of hydrogenase I from Clostridium pasteurianum. Biochemistry. 1991 Oct 8;30(40):9697-704.
9836629	Peters JW, Lanzilotta WN, Lemon BJ, Seefeldt LC: X-ray crystal structure of the Fe-only hydrogenase (CpI) from Clostridium pasteurianum to 1.8 angstrom resolution. Science. 1998 Dec 4;282(5395):1853-8.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
621

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
63829

# Drug_Target_3_Name:
Periplasmic [Fe] hydrogenase 1

# Drug_Target_3_Number_of_Residues:
574

# Drug_Target_3_PDB_ID:
1C4C

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00037	Fer4
PF00111	Fer2
PF02256	Fe_hyd_SSU
PF02906	Fe_hyd_lg_C

# Drug_Target_3_Protein_Sequence:
>Periplasmic [Fe] hydrogenase 1
MKTIIINGVQFNTDEDTTILKFARDNNIDISALCFLNNCNNDINKCEICTVEVEGTGLVT
ACDTLIEDGMIINTNSDAVNEKIKSRISQLLDIHEFKCGPCNRRENCEFLKLVIKYKARA
SKPFLPKDKTEYVDERSKSLTVDRTKCLLCGRCVNACGKNTETYAMKFLNKNGKTIIGAE
DEKCFDDTNCLLCGQCIIACPVAALSEKSHMDRVKNALNAPEKHVIVAMAPSVRASIGEL
FNMGFGVDVTGKIYTALRQLGFDKIFDINFGADMTIMEEATELVQRIENNGPFPMFTSCC
PGWVRQAENYYPELLNNLSSAKSPQQIFGTASKTYYPSISGLDPKNVFTVTVMPCTSKKF
EADRPQMEKDGLRDIDAVITTRELAKMIKDAKIPFAKLEDSEADPAMGEYSGAGAIFGAT
GGVMEAALRSAKDFAENAELEDIEYKQVRGLNGIKEAEVEINNNKYNVAVINGASNLFKF
MKSGMINEKQYHFIEVMACHGGCVNGGGQPHVNPKDLEKVDIKKVRASVLYNQDEHLSKR
KSHENTALVKMYQNYFGKPGEGRAHEILHFKYKK

# Drug_Target_3_Reaction:
H2 + 2 oxidized ferredoxin = 2 reduced ferredoxin + 2 H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P29166

# Drug_Target_3_SwissProt_Name:
PHF1_CLOPA

# Drug_Target_3_Synonyms:
CpI
EC 1.12.7.2
Fe-only hydrogenase

# Drug_Target_3_Theoretical_pI:
6.65

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00916
